Yifan Pharmaceutical Co Ltd (Yifan) discovers, develops, manufactures, and commercializes medicines, active pharmaceutical ingredients (APIs), and polymer products. Its products include advanced biologics such as Ryzneuta for chemotherapy-induced neutropenia, proprietary Traditional Chinese Medicine products, and niche injectable and oral therapies for critical care, oncology, neurology, and viral infections. Also, the company offers key vitamins, including D-calcium pantothenate and D-panthenol.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Yifan focuses on innovative product research and development (R&D) across four main business areas: biologics, small molecules, synthetic biologics, and traditional Chinese medicines (TCMs). The company has established a comprehensive R&D system that includes project evaluation, new drug screening, technology research, quality standard formulation, clinical research, and registration for approval. The aim is to promote the early marketing of products under research. The company has established five product R&D centers in China and the U.S. These centers are responsible for building a qualified team and an international R&D system that meets practical requirements. The supporting team within these centers manages the entire process of new drug research, from project evaluation and initiation to clinical trials and registration applications. Its R&D Personnel includes over 800, including approximately 200 MS and PhD holders. The company holds around 300 international/domestic patents and approximately 20 PCT patents. It partners with Jiangnan University, Zhejiang University of Technology, Amryis, and other top synthetic biologics companies. In FY2025, the company spent CNY291.3 million on its R&D activities, which as a percentage of revenue stood at 5.7%.